<DOC>
	<DOCNO>NCT00507143</DOCNO>
	<brief_summary>From 100 colorectal cancer patient treat FOLFIRI regimen kind irinotecan contain regimen , blood sample irinotecan metabolite level genotype relate metabolism collect . The association level genotypes treatment effect evaluate .</brief_summary>
	<brief_title>Study Genetic Polymorphisms Drug Transporters Orphan Nuclear Receptors Treatment Effects Irinotecan</brief_title>
	<detailed_description>For genotype-PD association , 50 colorectal cancer patient treat FOLFIRI enrol study . 50 additional colorectal patient treat kind irinotecan contain regimen enrol include 50 patient genotype-PD association , total 100 patient evaluate genotype-PK association . Blood sample PK analysis collect patient colorectal cancer 1st treatment cycle irinotecan 2nd , 3rd infusion . During 1st treatment cycle , blood drawn 0 h ( irinotecan infusion ) , 0.75 h , 1.5 h time range 2~8 h , 8~16 h , 24~32h 48~52 hour start irinotecan infusion 90 min additional blood collect 48~52 hour respective 2nd 3rd infusion . For 50 colorectal cancer patient treat FOLFIRI regimen , response treatment assess every 3 cycle . All assessment repeat end trial therapy . The RECIST criterion measurable disease follow toxicity evaluate accord NCI common toxicity criterion version 3.0 . Time disease progression calculate date study entry first objective documentation progressive disease . Response duration measure date patient first fulfill CR PR criterion first date objective documentation disease progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically diagnose unresectable metastatic colorectal cancer Performance status 0 , 1 2 ECOG criterion Disease status must measurable disease define RECIST criterion ( For genotypePD study ) Only nontarget lesion allow PK study No previous chemotherapy , radiotherapy target lesion , immunotherapy ; adjuvant chemotherapy fluoropyrimidines complete least 6 month ago allow ( For genotypePD study ) Previously treat patient allow PK study Life expectancy 3 month ( For genotypePD study ) Adequate major organ function Compliant patient followedup adequately Informed consent Active uncontrolled infection Pregnant breastfeed woman Patients systemic disease , especially cardiovascular disease , tolerate systemic chemotherapy Patients brain metastasis ( For genotypePD study ) Patients treat radiotherapy within 2 week ( For genotypePD study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Secondary</keyword>
	<keyword>irinotecan</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>SLCO1B1</keyword>
	<keyword>PXR</keyword>
</DOC>